142 related articles for article (PubMed ID: 18081307)
1. Engineered systems for detection and discovery of nuclear hormone-like compounds.
Gillies AR; Skretas G; Wood DW
Biotechnol Prog; 2008; 24(1):8-16. PubMed ID: 18081307
[TBL] [Abstract][Full Text] [Related]
2. Engineered chimeric enzymes as tools for drug discovery: generating reliable bacterial screens for the detection, discovery, and assessment of estrogen receptor modulators.
Skretas G; Meligova AK; Villalonga-Barber C; Mitsiou DJ; Alexis MN; Micha-Screttas M; Steele BR; Screttas CG; Wood DW
J Am Chem Soc; 2007 Jul; 129(27):8443-57. PubMed ID: 17569534
[TBL] [Abstract][Full Text] [Related]
3. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
Skerra A
FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
[TBL] [Abstract][Full Text] [Related]
4. A bacterial biosensor of endocrine modulators.
Skretas G; Wood DW
J Mol Biol; 2005 Jun; 349(3):464-74. PubMed ID: 15878176
[TBL] [Abstract][Full Text] [Related]
5. Digging deep into the pockets of orphan nuclear receptors: insights from structural studies.
Benoit G; Malewicz M; Perlmann T
Trends Cell Biol; 2004 Jul; 14(7):369-76. PubMed ID: 15246430
[TBL] [Abstract][Full Text] [Related]
6. Chemical biology of steroid and nuclear hormone receptors.
Biggins JB; Koh JT
Curr Opin Chem Biol; 2007 Feb; 11(1):99-110. PubMed ID: 17188557
[TBL] [Abstract][Full Text] [Related]
7. Engineered affinity proteins--generation and applications.
Grönwall C; Ståhl S
J Biotechnol; 2009 Mar; 140(3-4):254-69. PubMed ID: 19428722
[TBL] [Abstract][Full Text] [Related]
8. Ligand specificity of nuclear hormone receptors: sifting through promiscuity.
Noy N
Biochemistry; 2007 Nov; 46(47):13461-7. PubMed ID: 17983246
[TBL] [Abstract][Full Text] [Related]
9. Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands.
de Wolf FA; Brett GM
Pharmacol Rev; 2000 Jun; 52(2):207-36. PubMed ID: 10835100
[TBL] [Abstract][Full Text] [Related]
10. DNA-binding profiling of human hormone nuclear receptors via fluorescence correlation spectroscopy in a cell-free system.
Kobayashi T; Kodani Y; Nozawa A; Endo Y; Sawasaki T
FEBS Lett; 2008 Aug; 582(18):2737-44. PubMed ID: 18619963
[TBL] [Abstract][Full Text] [Related]
11. Nuclear hormone receptors in nematodes: evolution and function.
Taubert S; Ward JD; Yamamoto KR
Mol Cell Endocrinol; 2011 Mar; 334(1-2):49-55. PubMed ID: 20438802
[TBL] [Abstract][Full Text] [Related]
12. The rapid discovery of engineered antibodies.
Wang M; He M
IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
[TBL] [Abstract][Full Text] [Related]
13. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.
Schlehuber S; Skerra A
Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717
[TBL] [Abstract][Full Text] [Related]
14. Coactivators in assay design for nuclear hormone receptor drug discovery.
Chen T; Xie W; Agler M; Banks M
Assay Drug Dev Technol; 2003 Dec; 1(6):835-42. PubMed ID: 15090229
[TBL] [Abstract][Full Text] [Related]
15. Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: simulations using a novel multipoint steered molecular dynamics approach.
Martínez L; Polikarpov I; Skaf MS
J Phys Chem B; 2008 Aug; 112(34):10741-51. PubMed ID: 18681473
[TBL] [Abstract][Full Text] [Related]
16. Alternative non-antibody scaffolds for molecular recognition.
Skerra A
Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
[TBL] [Abstract][Full Text] [Related]
17. Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
Fan F; Hu R; Munzli A; Chen Y; Dunn RT; Weikl K; Strauch S; Schwandner R; Afshari CA; Hamadeh H; Nioi P
Toxicol Sci; 2015 Jun; 145(2):283-95. PubMed ID: 25752796
[TBL] [Abstract][Full Text] [Related]
18. Specificity of DNA-binding by the FAX-1 and NHR-67 nuclear receptors of Caenorhabditis elegans is partially mediated via a subclass-specific P-box residue.
DeMeo SD; Lombel RM; Cronin M; Smith EL; Snowflack DR; Reinert K; Clever S; Wightman B
BMC Mol Biol; 2008 Jan; 9():2. PubMed ID: 18179707
[TBL] [Abstract][Full Text] [Related]
19. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".
Schlehuber S; Skerra A
Drug Discov Today; 2005 Jan; 10(1):23-33. PubMed ID: 15676296
[TBL] [Abstract][Full Text] [Related]
20. Engineering allosteric protein switches by domain insertion.
Ostermeier M
Protein Eng Des Sel; 2005 Aug; 18(8):359-64. PubMed ID: 16043448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
